A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing
NCT ID: NCT05127772
Last Updated: 2023-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
126 participants
INTERVENTIONAL
2021-11-22
2023-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
NCT03375632
Study of of URC102 to Assess the Efficacy and Safety in Gout Patients
NCT04804111
A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
NCT05302388
A Safety and Tolerability Study of FCN-207 in Healthy Volunteers
NCT04622124
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04052932
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
single dose of HEC93077（pilot trial arm）
Healthy subjects receive single dose of HEC93077
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
single dose of HEC93077（Cohort 1）
Healthy subjects receive sinele dose of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
single dose of HEC93077（Cohort 2）
Healthy subjects receive sinele dose of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
single dose of HEC93077（Cohort 3,Fed/Fasting）
Following an overnight fast of at least 10 hours, a single dose of HEC93077 or placebo will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
single dose of HEC93077（Cohort 4）
Healthy subjects receive sinele dose of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
single dose of HEC93077（Cohort 5）
Healthy subjects receive sinele dose of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
single dose of HEC93077（Cohort 6）
Healthy subjects receive sinele dose of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
single dose of HEC93077（Cohort 7）
Healthy subjects receive sinele dose of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
multiple doses of HEC93077（ Cohort 8）
Healthy subjects receive multiple doses of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
multiple doses of HEC93077（ Cohort 9, Group 1)
Healthy subjects receive multiple doses of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
multiple doses of HEC93077（ Cohort 9, Gruop 2)
Hyperuricemia subjects receive multiple doses of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
multiple doses of HEC93077（ Cohort 10)
Healthy subjects receive multiple doses of HEC93077 or matching placebo
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HEC93077
Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
Placebo
Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects aged between 18 and 45 (both inclusive) years old.
3. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥19 and ≤28 kg/m2 at screening.
4. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).
5. Without Plan for pregnancy or pregnant within 3 months after enrollment throughout the trial.
6. Serum uric acid≥240 and\<420 at screening.
7. GFR≥90 mL/min/1.73 m2 at screening.
1. Patients who are willing and are able to provide a written informed consent to participate in the study.
2. Patients aged between 18 and 60 (both inclusive) years old.
3. Patients has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥19 and ≤30 kg/m2 at screening.
4. During screening period, serum uric acid was ≥480 µmol/L twice on different days.Patients are considered to need to lower UA with a long term therapy;
5. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout the trial.
6. GFR≥90 mL/min/1.73 m2 at screening.
Exclusion Criteria
2. A history of gastrointestinal, liver, or kidney disease or surgery prior to screening that could potentially affect the absorption, distribution, metabolism, and excretion of the test drug (except for uncomplicated appendectomy and hernia repair);
3. History of urolithiasis or ultrasound screening showed urolithiasis, renal/ureteral malformation, unirenal or renal atrophy, polycystic kidney and other urological diseases
4. History of gout and/or hyperuricemia
5. Acute illness or concomitant use from signing the ICF to initial dosing.
6. Known allergic reactions or hypersensitivity to any excipient of the drug formulation(s)， anaphylaxis physique.(Allergic to more than 3 foods and/or medications)
7. History of alcoholism or drink regularly within 3 months prior to the study(defined as Alcohol consumption of \> 21 units/week), or positive results from alcohol breath test at screening.
8. History of drug abuse, or use of drugs within 2 years prior to the study,or positive results from urine drug screen test at screening.
9. Regular smoking of more than 10 cigarettes per day within 3 months before screening period, or inability to refrain from smoking during the course of the study after signing ICF.
10. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP antibodies at screening.
11. Use of any prescription or non-prescription medications、vitamin and traditional Chinese medicine within 2 weeks prior to initial dosing,or use of any mediciations which affect UA synthesize,metabolize and excrete within 4 weeks prior to initial dosing.
12. Use of any medications known to strongly inhibit and/or induce cytochrome P enzyme drug metabolism within 4 weeks prior to initial dosing.
13. Have taken any food or drink that affects CYP3A4 and/or CYP1A2 metabolic enzymes within 2 days prior to initial dosing,such as grapefruit or grapefruit drink.
14. Have taken chocolate, any food or drink containing caffeine or rich in xanthine within 72 hours prior to initial dosing.
15. Have taken any alcoholic product within 48 hours prior to initial dosing.
16. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
17. Subjects who plan to receive or have had organ transplants.
18. Females who are lactating/breastfeeding, or positive result from pregnancy test for women of child-bearing potential.
19. Subjects who participated in another clinical trial within 3 months prior to initial dosing.
20. Subjects who canot tolerate fat food.(only suitable to FE trial)
21. Subjects who maynot complete for other reasons.
22. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.
Hyperuricemia Patients：
1. Patients with myocardial infarction, angina pectoris, percutaneous coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack within 6 months prior to screening.
2. History of acute gout attack prior to initial dosing;
3. Acute illness or use of a contraindicated drug under the protocol from signing the ICF to initial dosing.
4. At screening,AST or ALT or TBIL \>1.2 × ULN, or sCr \>ULN，or HbA1c\>8%.
4.Investigator judged the following conditons unsuitable for inclusion:Medical history, physical examination, electrocardiogram, chest X-ray, ultrasonic examination of digestive system , ultrasonic examination of urinary system and laboratory examination have abnormal and clinical significance.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunshine Lake Pharma Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Universicity Care of Luzhong Hospital
Zibo, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEC93077-HUA-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.